A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults  by Stephan, Dominique et al.
Archives of Cardiovascular Disease (2015) 108, 453—459
Available  online  at
ScienceDirect
www.sciencedirect.com
REVIEW
A  critical  appraisal  of  the  guidelines  from
France,  the  UK,  Europe  and  the  USA  for  the
management  of  hypertension  in  adults
Lecture  critique  des  recommandations  pour  la  prise  en  charge  de
l’hypertension  artérielle  de  l’adulte,  franc¸aises,  anglaises,  européennes  et
nord-américaines
Dominique  Stephan ∗,  Sébastien  Gaertner,
Elena-Mihaela  Cordeanu
Department  of  vascular  disease,  hypertension  and  clinical  pharmacology,  Strasbourg  regional
university  hospital,  Strasbourg,  France
Received  20  March  2015;  accepted  7  May  2015
Available  online  22  June  2015
KEYWORDS
Hypertension;
Guidelines;
Target
Summary  Hypertension  is  the  leading  cause  of  death  in  developed  countries;  its  management
is the  subject  of  guidelines  that  are  regularly  reviewed  and  updated.  However,  the  guide-
lines from  France,  the  UK,  Europe  and  the  USA  differ.  Some  recommendations  are  graded,
whereas others  are  not.  All  recommendations  emphasize  the  role  of  alternative  methods  for
clinical measurement  of  blood  pressure,  such  as  ambulatory  blood  pressure  measurement
(ABPM) or  self-measurement.  The  UK  guideline  recommends  that  the  diagnosis  of  hyperten-
sion should  be  established  by  ABPM.  The  USA  guideline  recommends  a  target  of  ≤  150/90  mmHg
for patients  aged  >  60  years.  The  French  guideline  recommends  that  the  target  blood  pressure
remains at  <  140/90  mmHg,  with  <  150  mmHg  for  patients  aged  >  80  years.  Systolic  blood  pres-
sure between  130  and  139  mmHg  and  diastolic  blood  pressure  <  90  mmHg  are  recommended  for
diabetic patients  and  those  with  chronic  kidney  disease.  The  French  Society  of  Hypertension
(SFHTA) guideline  is  unique  in  recommending  a  dedicated  consultation  to  announce  the  diagnosis
Abbreviations: ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor
blocker; DBP, diastolic blood pressure; ESH, European Society of Hypertension; HAS, French National Authority for Health (Haute Autorité
de Santé); JNC-8, Eighth Joint National Committee; NICE, National Institute for Health and Care Excellence; SBP, systolic blood pressure;
SFHTA, French Society of Hypertension (Société franc¸aise d’hypertension artérielle).
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to  the  patient.  In  the  French  and  European  guidelines,  diuretics,  beta-blockers,  calcium  antago-
nists, angiotensin-converting  enzyme  (ACE)  inhibitors  and  angiotensin  II  type  1  receptor  blockers
(ARBs) remain  indicated  as  ﬁrst-line  therapy  for  hypertension;  if  the  target  blood  pressure  is
not achieved,  they  recommend  combining  two  active  substances.  The  UK  guideline  recommends
ACE inhibitors  or  ARBs  as  ﬁrst-line  therapy  for  patients  aged  <  55  years;  calcium  antagonists  are
advised for  patients  aged  >  55  years  and  for  black  patients.  The  USA  guideline  advises  treat-
ing non-black  patients,  including  those  with  diabetes,  with  thiazides,  calcium  antagonists,  ACE
inhibitors or  ARBs;  for  black  patients,  including  those  with  diabetes,  it  recommends  thiazide
and calcium  antagonists.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’hypertension  est  la  principale  cause  de  décès  dans  les  pays  développés.  Sa  prise
en charge  fait  l’objet  de  recommandations  qui  sont  régulièrement  réactualisées.  Cepen-
dant, les  recommandations  franc¸aises,  britanniques,  européennes  et  nord-américaines  diffèrent
notablement.  Certaines  recommandations  sont  gradées  d’autres  ne  le  sont  pas.  Toutes  les
recommandations  soulignent  l’intérêt  de  méthodes  alternatives  à  la  mesure  clinique  de  la
pression artérielle  telle  la  mesure  ambulatoire  ou  l’auto-mesure.  Pour  les  recommandations
anglaises,  le  diagnostic  de  l’hypertension  doit  être  établi  par  mesure  ambulatoire  de  la  PA.
Aux États-Unis,  le  JNC-8  recommande  une  cible  de  ≤  150/90  mmHg  pour  les  patients  de  plus
de 60  ans.  Pour  les  recommandations  franc¸aises,  la  PA  cible  recommandée  reste  <  140/90  mmHg
et <  150  mmHg  pour  les  plus  de  80  ans,  une  PAS  comprise  entre  130  et  139  mmHg  et  une  pression
artérielle diastolique  <  90  mmHg  sont  recommandées  chez  les  diabétiques  et  insufﬁsants  rénaux.
La recommandation  franc¸aise  est  unique  en  proposant  une  consultation  dédiée  à  l’annonce  du
diagnostic  au  patient.  Selon  les  directives  franc¸aises  et  européennes,  les  diurétiques,  bêta-
bloquants,  inhibiteurs  calciques,  inhibiteurs  de  l’enzyme  de  conversion  de  l’angiotensine  (IEC)
et bloqueurs  des  récepteurs  de  l’angiotensine  2  (ARA2)  restent  indiqué  comme  traitement  de
première intention  de  l’hypertension.  Si  la  PA  cible  n’est  pas  atteinte,  il  est  recommandé  de
combiner  deux  substances  actives.  Au  Royaume-Uni,  IEC  ou  ARA2  sont  recommandés  comme
traitement  de  première  intention  pour  les  patients  âgés  de  moins  de  55  ans.  Les  antagonistes
calciques  sont  conseillées  pour  les  patients  âgés  de  plus  de  55  ans  ou  des  personnes  noires.  La
recommandation  US  conseille  le  traitement  des  patients  non  noirs,  y  compris  les  diabétiques,
avec les  diurétiques  thiazidiques,  antagonistes  calciques,  IEC  ou  ARA2.  Pour  les  patients  noirs,
y compris  les  diabétiques,  thiazidiques  et  antagonistes  calciques  sont  recommandés.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ccording  to  the  author  Paul  Valéry,  ‘everything  simple  is
alse,  everything  complex  is  unusable’.  This  maxim  sums
p  the  difﬁculty  facing  any  team  tasked  with  developing
 guideline:  if  they  aim  for  simplicity,  they  will  probably
eave  out  many  special  cases;  and  if  all  cases  are  covered,
he  result  becomes  so  complex  that  nobody  can  understand
ow  it  works.  In  other  words,  there  are  no  miracle  solu-
ions  or  magic  formulae.  Guidelines  on  the  management  of
ypertension  are  no  exception.  The  2-year  period  from  2013
o  2014  saw  the  publication  of  new  hypertension  guidelines
n  France  by  the  French  Society  of  Hypertension  (Société
ranc¸aise  d’Hypertension  Artérielle  [SFHTA])  [1],  in  Europe
y  the  European  Society  of  Hypertension  (ESH)  [2], and  in  the
SA  by  the  Eighth  Joint  National  Committee  (JNC-8)  [3].  In
he  UK,  the  guidelines  were  updated  in  2011  by  the  National
nstitute  for  Health  and  Care  Excellence  (NICE)  [4]. These
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a
t
tuidelines  differ  in  both  content  and  form.  As  the  leading
ause  of  death  worldwide,  the  management  of  this  condi-
ion  is  as  important  as  ever,  yet  the  advice  differs  between
ountries  and  continents.  This  critical  appraisal  summarizes
he  key  recommendations  of  these  guidelines,  highlighting
oints  on  which  they  agree  and  disagree,  as  well  as  unique
eatures.
 leaﬂet or a book?
he  ideal  length  for  a  guideline  is  a thorny  issue.  A  short
ocument  is  easy  to  read  and  use,  but  inevitably  simplistic,
hile  an  intentionally  exhaustive  document  that  exceeds
0  pages  is  difﬁcult  to  use  in  routine  practice.  The  French
nd  European  guidelines  sit  at  opposite  ends  of  this  spec-
rum:  the  French  guideline  is  just  four  pages  long  and  con-
ains  39  references,  while  the  European  document  runs  to  77
urop
p
m
s
r
d
r
a
H
m
H
p
t
t
w
e
r
i
s
c
t
i
s
u
I
t
t
i
s
t
h
m
i
t
s
h
t
a
i
m
b
l
s
s
a
r
m
h
b
a
a
w
s
tA  critical  appraisal  of  the  guidelines  from  France,  the  UK,  E
pages  and  contains  735  references.  The  USA  and  UK  guide-
lines  are  14  and  27  pages  long,  respectively.  The  SFHTA,  JNC-
8  and  NICE  had  evidently  taken  the  view  that  their  guidelines
should  be  short  enough  to  ensure  that  they  are  read.  The
European  guideline,  on  the  other  hand,  is  intended  as  a  refe-
rence  work,  and  addresses  every  situation  encountered  in
the  initial  management,  workup  and  treatment  of  hyperten-
sion,  including  techniques  currently  under  evaluation,  such
as  renal  denervation.  This  detailed  document  nevertheless
includes  many  tables  summarizing  the  positions  adopted.  It
is  clearly  intended  for  specialists.  In  contrast,  the  French
guideline  targets  generalists  and  its  simplicity  is  a  stated
aim;  it  is  divided  into  short,  deliberately  didactic  subsec-
tions.  This  guideline  does  not  address  speciﬁc  situations,  but
proposes  a  general  plan  of  action  for  managing  hypertension
in  adults.  Thus,  for  example,  resistant  hypertension  is  dealt
with  in  a  separate  document  that  differs  in  form  and  length.
Should recommendations be graded?
As  clinical  practice  is  nowadays  based  on  evidence  and  as
little  as  possible  on  opinion,  the  selection  of  documents
and  articles  on  which  to  base  recommendations  is  a  crucial
stage;  it  makes  it  possible  to  weigh  up  expert  opinion  and
naturally  results  in  a  grading  of  recommendations.
For  the  USA  guideline,  a  panel  of  methodologists  selected
the  articles  most  relevant  to  the  questions  posed,  and
passed  them  on  to  the  writing  panel.  The  selection  criteria
were  extremely  restrictive,  in  that  only  publications  refer-
ring  to  clinical  trials  in  hypertension  were  retained.
The  French  guideline  lists  few  references,  including
former  guidelines  (issued  in  2005  by  the  French  National
Authority  for  Health  [Haute  Autorité  de  santé;  HAS])  [5],
guidelines  from  other  countries  or  scientiﬁc  societies  (NICE,
ESH)  and  meta-analyses.  The  USA  and  European  recommen-
dations  are  graded  in  the  usual  manner,  ranging  from  strong
recommendations,  based  on  clinical  trials  of  high  method-
ological  quality  that  included  a  large  number  of  patients,
down  to  more  empirical  expert  opinions,  with  a  series  of
intermediate  levels  in  between.  The  French  and  UK  recom-
mendations  are  not  graded,  as  the  intention  was  to  convey
a  straightforward  message  to  clinicians.
Do  levels  of  evidence  matter  to  typical  prescribers  who
are  not  hypertension  specialists?  It  would  be  useful  to  answer
this  question  by  conducting  a  survey  among  the  clinicians
targeted  by  the  guideline.  The  European  guideline  strongly
recommends  renin-angiotensin  system  blockers  in  unilateral
renal  artery  stenosis  (class  I  recommendation),  but  tempers
it  with  a  B  grading  for  its  level  of  evidence,  signaling  that
it  is  supported  by  clinical  trials  of  limited  size.  The  possibil-
ity  of  adjusting  recommendations  through  grading  appears
better  suited  to  evidence-based  rather  than  opinion-based
medicine.  The  danger,  however,  is  that  the  message  can
become  overly  complex  and  convoluted.
Diagnosing hypertension: out-of-ofﬁce
measurements are best!A  paradox  highlighted  by  all  of  the  guidelines  is  that
ofﬁce  blood  pressure  measurement  is  undoubtedly  the
worst  method  for  diagnosing  and  monitoring  hypertensive
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atients.  Alternative  methods  —  ambulatory  blood  pressure
onitoring  (ABPM)  or  self-measurement  —  must  now  be  con-
idered  to  have  an  important  if  not  essential  role.  The  SFHTA
ecommends  out-of-ofﬁce  measurements  to  conﬁrm  the
iagnosis  of  hypertension,  but  does  not  specify  whether  this
efers  to  self-measurement  or  ABPM.  However,  the  SFHTA
nd  the  French  Committee  for  the  Prevention  and  Control  of
ypertension  (CFLHTA)  have  been  promoting  the  use  of  self-
easurement  for  several  years.  In  fact,  the  French  National
ealth  Insurance  Fund  (CNAM)  is  going  to  offer  home  blood
ressure  monitors  to  primary  care  physicians  as  an  aid  to
he  diagnosis  of  hypertension.  The  aim  of  this  initiative  is
o  distinguish  true  hypertension  from  white  coat  syndrome,
hich  leads  to  overdiagnosis,  and  to  reduce  the  cost  to  soci-
ty  of  unnecessary  treatment.  However,  recent  studies  have
evealed  that  the  conditions  under  which  self-measurement
s  performed,  and  therefore  its  reliability,  can  be  far  from
atisfactory.  Although  patients  generally  master  the  techni-
al  aspects  of  self-measurement,  the  major  advantages  of
his  method  are  undermined  by  failure  to  take  enough  read-
ngs,  to  take  them  at  the  required  frequency  or  to  record  and
ubmit  them,  which  ultimately  means  that  the  results  are
nusable  and  have  little  impact  on  blood  pressure  control.
f  self-measurement  is  to  make  a  positive  contribution  to
he  management  of  hypertensive  patients,  physicians  must
herefore  receive  training  and  patients  must  be  properly
nformed.
The  UK  guideline  recommends  that  suspected  hyperten-
ion  should  be  conﬁrmed  by  24-hour  ABPM.  ABPM  appears
o  be  a  more  sensitive  and  speciﬁc  method  for  diagnosing
ypertension  than  multiple  ofﬁce  blood  pressure  measure-
ents  at  repeated  appointments.  NICE  also  claims  that  ABPM
s  more  cost-effective  than  home  self-measurement,  and
hat  self-measurement  is  more  effective  than  ofﬁce  mea-
urements,  but  less  effective  than  ABPM.  It  is  thought,
owever,  that  5—10%  of  patients  do  not  tolerate  ABPM,  and
hat  no  automated  systems  are  suitable  for  patients  with
trial  ﬁbrillation.  According  to  NICE,  the  use  of  ABPM  results
n  fewer  visits  to  the  physician  and  earlier  initiation  of  treat-
ent  for  patients  who  require  therapy.  Including  the  cost  of
uying  the  equipment,  the  NICE  expert  committee  calcu-
ated  that  it  would  be  cost  neutral  in  2  years  and  produce
avings  after  3  years.
According  to  the  ESH,  alternatives  to  ofﬁce  blood  pres-
ure  measurement  (self-measurement  or  ABPM)  are  a  useful
djunct  to  conventional  blood  pressure  measurement,  which
emains  the  gold  standard  for  screening  for,  diagnosing  and
onitoring  hypertension.
The  USA  guideline  does  not  address  the  diagnosis  of
ypertension.  This  document  focuses  on  a  limited  num-
er  of  objectives:  to  deﬁne  the  blood  pressure  thresholds
bove  which  therapy  should  be  initiated,  treatment  goals
nd  treatment  strategies.  A  recap  of  the  conditions  under
hich  blood  pressure  is  measured,  particularly  the  standard
phygmomanometer  method,  is  included  in  the  supplemen-
al  content.lood pressure goals
he  USA  guideline  revives  the  old  debate  about  the  blood
ressure  thresholds  above  which  treatment  is  justiﬁed,  and
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he  blood  pressure  targets  to  achieve  through  treatment,
hich  in  reality  amount  to  the  same  thing.  This  guideline,
rafted  by  a  panel  of  experts  led  by  a  professor  of  family
edicine,  focuses  on  three  questions:  what  are  the  blood
ressure  values  above  which  treatment  initiation  leads  to
 reduction  in  cardiovascular  events;  what  blood  pressure
argets  should  be  achieved  in  order  to  reduce  cardiovas-
ular  events;  and  what  is  the  harm-beneﬁt  balance  of  the
arious  antihypertensive  drug  classes  in  the  treatment  of
ypertension?  The  rationale  for  developing  this  guideline  is
s  follows:  the  optimal  target  blood  pressure  for  antihyper-
ensive  treatment  is  unclear,  including  in  subgroups  (black
atients,  patients  with  diabetes  or  chronic  kidney  disease);
etting  blood  pressure  goals  too  low  has  led  to  overmedi-
ation  of  hypertensive  patients  and  an  increase  in  adverse
ffects;  blood  pressure  goals  should  probably  be  raised,
n  order  to  limit  treatment  intensiﬁcation.  New  treatment
argets  were  deﬁned,  based  on  publications  selected  by
 group  of  methodologists,  using  strict  criteria,  and  then
orwarded  to  the  writing  panel.  Following  the  recent  publi-
ation  of  two  Japanese  clinical  trials  showing  that  reducing
ystolic  blood  pressure  (SBP)  to  136—137  mmHg  was  no  bet-
er  than  a  goal  of  <  142—145  mmHg  in  terms  of  reducing
he  incidence  of  the  complications  of  hypertension,  the
SA  guideline  recommends  a  target  of  <  150/90  mmHg  for
atients  aged  >  60  years.  The  blood  pressure  goal  for  patients
ged  <  60  years  remains  <  140/90  mmHg.  In  patients  with  dia-
etes  or  chronic  kidney  disease,  the  blood  pressure  goal
as  been  increased  from  ≤  130/80  mmHg  to  <  140/90  mmHg.
 recent  study  estimated  the  proportion  of  hypertensive
dults  in  the  USA  affected  by  the  change  in  these  recommen-
ations  [6].  The  new  blood  pressure  goals  would  reduce  the
umber  of  persons  eligible  for  antihypertensive  therapy  by
.8  millions.  The  proportion  of  hypertensives  meeting  blood
ressure  goals  would  increase  from  40.6%  (based  on  the  JNC-
 targets)  to  56.5%  (based  on  the  newly  determined  targets)
6].
The  French  guideline  gives  more  discretion  to  clinicians.
he  target  blood  pressure  it  recommends,  including  for
atients  with  diabetes  or  chronic  kidney  disease,  is  an  SBP
etween  130  and  139  mmHg  and  a  diastolic  blood  pressure
DBP)  <  90  mmHg,  but  lower  goals  can  be  proposed  for  cer-
ain  patients,  after  consulting  a  specialist.
The  European  guideline  draws  a  distinction  between
high  normal’  blood  pressure  and  three  grades  of  hyper-
ension.  A  two-way  table  is  used  to  decide  at  which  stage
atients  should  be  treated,  where  the  columns  correspond
o  blood  pressure  and  the  rows  to  the  number  of  risk  fac-
ors,  the  presence  of  target  organ  disease,  chronic  kidney
isease  or  diabetes  and  the  patient’s  status  (e.g.  secondary
revention).  The  different  colours  indicate  the  overall  car-
iovascular  risk  level,  where  green  corresponds  to  the
owest  risk  and  red  to  the  highest.  This  table  may  appear
omplicated  and  relatively  unusable  in  practice.  However,
t  highlights  the  value  of  taking  into  account  the  intensity
f  the  risk  factor  considered  —  in  this  case  hypertension
everity  —  and  of  estimating  overall  cardiovascular  risk  when
eciding  whether  to  treat  patients.  This  observation  is  based
n  the  results  of  clinical  trials  conducted  in  patients  at  ‘high
ardiovascular  risk’,  in  whom  it  was  shown  that  a statin
r  renin-angiotensin  system  blocker  signiﬁcantly  reduced
he  incidence  of  cardiovascular  complications.  For  patients
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ategorized  as  having  a  high  cardiovascular  risk  (e.g.  a  dia-
etic  with  a  reduced  glomerular  ﬁltration  rate),  it  is  only
ogical  to  prescribe  treatment  proven  to  reduce  overall
ardiovascular  risk,  speciﬁcally  a  renin-angiotensin  system
locker,  regardless  of  whether  they  are  also  hypertensive.  It
s  worth  mentioning  that  the  HOPE  study  [7],  which,  among
ther  things,  lent  support  to  the  ESH’s  paradigm  of  the  ben-
ﬁt  of  treating  patients  with  high  cardiovascular  risk,  was
ejected  by  the  JNC-8  because  the  patients  enrolled  in  this
rial  were  not  all  hypertensive.
France’s  2005  HAS  guideline  also  contained  a  two-way
able,  a  similar  (but  less  complicated)  version  of  the  ESH
able,  but  it  was  omitted  from  the  brief  overview  of  the
013  SFHTA  recommendations.  The  concept  was  no  doubt
onsidered  unhelpful  for  generalists.
reaking the bad news
he  French  SFHTA  guideline  is  unique  in  recommending  a
edicated  consultation  to  announce  the  diagnosis  to  the
atient.  Its  purpose  is  to  inform  the  patient  about  hyperten-
ion  and  its  consequences,  the  available  pharmacotherapy
nd  the  objectives  of  treatment,  and  then  to  ascertain  the
atient’s  opinion  and  evaluate  his  or  her  decisional  ‘bal-
nce  sheet’  (the  beneﬁts  and  drawbacks  of  treatment  from
he  patient’s  perspective).  The  intention  is  commendable,
lthough  the  concept  of  ‘breaking  the  bad  news’  may  seem
dd  for  a  condition  that  is  a  risk  factor  rather  than  a  disease.
ypertension  is  deﬁned  by  blood  pressure  values  at  which
he  increased  incidence  of  cardiovascular  complications
ecomes  signiﬁcant.  Rather  than  following  a  bimodal  distri-
ution,  with  normotensives  on  one  hand  and  hypertensives
n  the  other,  forming  two  distinct  states  of  ‘wellness’  versus
sickness’,  its  distribution  is  unimodal,  forming  a  contin-
um  of  increasing  blood  pressure  and  increasing  risk.  In
evere  hypertension  (blood  pressure  >  180/110  mmHg)  the
isk  is  sufﬁciently  high  to  warrant  a  rapid  decision  concern-
ng  treatment,  which  may  justify  a  dedicated  consultation
o  disclose  and  discuss  the  diagnosis.  This  situation  is  not  the
orm,  however.  On  the  contrary,  in  grade  1  or  2  hypertension
initial  SBP  between  140  and  179  mmHg  and/or  DBP  between
0  and  109  mmHg),  the  variability  of  blood  pressure  means
hat  it  cannot  be  assumed  that  the  patient  is  usually  hyper-
ensive;  the  individual  risk  is  not  sufﬁciently  high  to  justify
mmediate  initiation  of  antihypertensive  medication  [5].  In
hese  cases,  the  decision  about  whether  or  not  to  prescribe
edical  therapy  is  only  taken  after  a  3—6-month  observa-
ion  period,  to  include  at  least  three  consultations  and  at
east  two  blood  pressure  measurements  per  consultation.
on-pharmacological  measures  to  lower  blood  pressure  and
educe  risk  cofactors  are  put  in  place  during  this  observation
eriod.  In  these  situations,  which  account  for  the  majority
f  cases,  at  what  point  should  the  clinician  break  the  bad
ews?  As  soon  as  high  readings  are  recorded?  As  mentioned
bove,  it  cannot  be  assumed  from  one  reading  that  the
atient  is  usually  hypertensive,  because  blood  pressure  is
ariable.  During  the  observation  period?  This  period,  with  its
uccessive  appointments,  could  well  offer  an  ideal  opportu-
ity  to  inform  and  educate  patients  and,  where  appropriate,
o  help  them  understand  the  beneﬁts  of  treatment,  with-
ut  a  dramatic  announcement  as  if  hypertension  were  a
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Table  1  Comparison  of  the  guidelines  on  the  management  of  hypertension.
France  (SFHTA)  UK  (NICE)  Europe  (ESH)  USA  (JNC-8)
Number  of
pages
4  27  77  14
References  39  735  45
Grading  No  No  Yes  Yes
Situations  Limited  Limited  Broad  Limited
Blood  pressure
targets
<  60  years  <  140/90  mmHg  <  140/90  mmHg  <  140/90  mmHg  <  140/90  mmHg
>  60  years  <  150/90  mmHg
>  80  years  <  150  mmHg  <  140—150  mmHg  Not  speciﬁcally
mentioned
Diabetes  130—139/  <  90  mmHg  <  140/90  mmHg
uncomplicated
diabetes;
<  130/80  mmHg
complicated
diabetes
< 140/85  mmHg  <  140/90  mmHg
Chronic
kidney
disease
130—139/  <  90  mmHg  <  140/90  mmHg  <  140/90  mmHg
Diagnostic
methods
Ofﬁce,  self-
measurement  or
ABPM
ABPM  Ofﬁce,
self-measurement  or
ABPM
Not  discussed  in
document
Treatment
First-line
therapy
Thiazides,
beta-blockersa,
CAs,  RAS  blockers
RAS  blockers  if
<  55  years;  CAs  if
>  55  years  or
black
Thiazides,
beta-blockers,  CAs,
RAS  blockers
Thiazides,  CAs,  RAS
blockers;  if  black,
thiazides  or  CAs
alone  or  combined
Combination  as
ﬁrst-line  therapy
if  high-risk  or
severe
hypertension
Combination
possible  as  ﬁrst-line
therapy
Second-line
therapy
Combine,  but
avoid  combining
different  RAS
blockers;
precaution  if
beta-blockers
and  diuretics
RAS
blockers  +  CAs
Increase
monotherapy  or
switch  to  another
class  or  combine;
avoid  combining
different  RAS
blockers
Increase
monotherapy  or
switch  to  another
class  or  combine;
avoid  combining
different  RAS
blockers
Third-line
therapy
RAS  block-
ers  +  thiazides  +  CAs
RAS  block-
ers  +  thiazides  +  CAs
RAS block-
ers  +  thiazides  +  CAs
RAS  block-
ers  +  thiazides  +  CAs
Diabetes  RAS  blockers  if
microalbuminuria
Outside  the  scope
of  the  guidelineb
All  classes;  RAS
blockers  if
microalbuminuria
Thiazides,  CAs,  RAS
blockers
Chronic
kidney
disease
Not  mentioned  Outside  the  scope
of  the  guidelineb
RAS  blockers  if
microalbuminuria  or
proteinuria
RAS  blockers  alone
or  combined
ABPM: ambulatory blood pressure monitoring; CA: long-acting dihydropyridine calcium antagonist; ESH: European Society of Hyper-
tension; JNC-8: Eighth Joint National Committee; NICE: National Institute for Health and Care Excellence; SFHTA: French Society of
Hypertension (Société Franc¸aise d’Hypertension Artérielle); RAS: renin-angiotensin system.
a Beta-blockers appear less effective than other classes for stroke prevention.
b Speciﬁc guidelines for these indications.
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erminal  illness.  It  would,  perhaps,  be  useful  to  conduct
 clinical  trial  to  see  whether  a  dedicated  consultation  to
nnounce  and  discuss  the  diagnosis  of  hypertension  actu-
lly  increases  the  proportion  of  patients  who  ultimately
chieve  blood  pressure  control.  Finally,  as  the  average  gen-
ral  practice  consultation  in  France  lasts  16  minutes,  and
hese  consultations  will  necessarily  take  longer,  it  will  be
mportant  to  make  the  best  possible  use  of  the  time.
reatment
he  guidelines  also  differ  on  the  thorny  question  of  the
reatment  of  hypertension  (Table  1).  According  to  the
FHTA,  ﬁve  antihypertensive  drug  classes  remain  indi-
ated  as  ﬁrst-line  therapy  for  hypertension:  diuretics,
eta-blockers,  calcium  antagonists,  angiotensin-converting
nzyme  (ACE)  inhibitors  and  angiotensin  II  type  1  receptor
lockers  (ARBs).  If  the  target  blood  pressure  is  not  achieved,
t  recommends  combining  two  active  substances,  prefer-
bly  in  a  single  tablet  (ﬁxed-dose  combination  therapy).  The
rench  guideline  no  longer  recommends  particular  combina-
ions.  The  2005  HAS  guideline  included  a  diagram  showing
hich  combinations  were  recommended  (in  the  shape  of
 boat,  with  some  drug  classes  in  the  hold  and  others  on
he  deck),  but  it  is  absent  from  the  2013  document,  appar-
ntly  giving  free  rein  to  clinicians  to  use  any  combination
f  these  drugs.  The  new  guideline  does  state,  however,  that
wo  renin-angiotensin  system  blockers  should  not  be  com-
ined,  and  that  the  combination  of  a  beta-blocker  with  a
iuretic  increases  the  risk  of  diabetes.  However,  if  hyper-
ension  is  uncontrolled  after  6  months,  the  SFHTA  guideline
ecommends  checking  that  triple  antihypertensive  therapy
as  been  prescribed  at  optimal  doses,  including  a renin-
ngiotensin  system  blocker,  a  thiazide  diuretic  and  a  calcium
ntagonist.  These  three  antihypertensive  drug  classes  are
he  ones  that  most  of  the  guidelines  recommend  combining
n  third-line  therapy,  but  what  happens  when  beta-blockers
ave  already  been  prescribed  as  ﬁrst-line  therapy  or  as  part
f  combined  second-line  therapy,  as  the  SFHTA  recommen-
ations  permit?  The  diagram  in  the  SFHTA  guideline  implies
hat  these  drugs  will  have  been  replaced  at  some  point.
he  question  remains,  why  recommend  them  for  ﬁrst-line
herapy  if  they  will  later  have  to  be  replaced?
The  UK  guideline  takes  a  more  linear  approach,  in  that
t  recommends  ACE  inhibitors  or  ARBs  as  ﬁrst-line  therapy
treatment  A)  for  patients  aged  <  55  years.  Calcium  antago-
ists  (treatment  C)  are  advised  for  patients  aged  >  55  years
r  black  patients,  unless  they  have  edema  or  a  risk  of  heart
ailure,  in  which  case  diuretics  are  recommended.  At  step
,  NICE  recommends  combining  a  renin-angiotensin  system
locker  with  a  calcium  antagonist.  At  step  3,  a  thiazide
iuretic  (treatment  D)  should  be  combined  with  A  and  C.
egarding  the  choice  of  diuretic,  the  data  on  chlortali-
one  12.5  or  25  mg  (withdrawn  from  the  market  in  France)
nd  indapamide  1.25  or  2.5  mg  seem  more  robust  than  for
ydrochlorothiazide,  probably  due  to  underdosing  of  this
rug  in  clinical  trials.  The  USA  guideline  advises  treating
on-black  patients,  including  those  with  diabetes,  with  thi-
zides,  calcium  antagonists,  ACE  inhibitors  or  ARBs.  For
lack  patients,  including  those  with  diabetes,  it  recom-
ends  thiazide  and  calcium  antagonists.  It  also  advises  that
o
i
b
tD.  Stephan  et  al.
atients  aged  >  18  years  with  chronic  renal  disease  should
eceive  a  renin-angiotensin  system  blocker.
hat about beta-blockers?
either  NICE  (UK)  nor  the  JNC-8  (USA)  recommends  beta-
lockers  as  ﬁrst-line  drugs.  According  to  the  JNC-8,  this  is
ased  on  the  LIFE  study,  which,  together  with  the  ASCOT
tudy,  showed  an  excess  of  cardiovascular  events,  particu-
arly  stroke,  in  the  beta-blocker  group  compared  with  the
RB  group  [8,9].
Beta-blockers  are  allowed  as  ﬁrst-line  therapy,  however,
n  the  French  and  European  guidelines.  But  the  SFHTA  tem-
ers  this  recommendation  by  stating  that  beta-blockers
ppear  to  be  less  effective  than  the  other  classes  in  stroke
revention.  According  to  the  French  and  European  guide-
ines,  third-line  therapy  must  use  a  renin-angiotensin  system
locker  with  a calcium  antagonist  and  a diuretic.  This  raises
he  question  of  what  to  do  when  the  patient  was  previously
aking  a  beta-blocker.  Should  it  be  withdrawn  and  replaced
ith  a  drug  from  one  of  the  three  recommended  classes?
iven  that  about  70%  of  hypertensives  require  a  combina-
ion  of  at  least  two  agents,  the  question  remains  as  to  why
eta-blockers  are  still  recommended  for  ﬁrst-line  therapy  if
hey  have  no  place  in  third-line  therapy.  According  to  the
K  guideline,  beta-blockers  can  be  used  in  the  fourth  step
f  treatment  adjustment.  According  to  JNC-8,  the  additional
roperties  of  alpha-blocking  and  vasodilating  beta-blockers
re  irrelevant  for  the  treatment  of  hypertension.
hat to do in practice
lthough  different  in  presentation,  content  and  expected
se,  each  of  these  four  guidelines  aims  to  become  a  useful
ool  for  the  practitioner,  whether  generalist  or  special-
st,  confronted  with  hypertensive  patients,  and  to  respond
o  unanswered  questions.  After  focusing  on  their  differ-
nt  approaches,  one  could  highlight  their  resemblances.
ndeed,  there  is  a  global  tendency  to  generalize  the  tar-
et  goal  of  a  BP  <  140/90  mmHg,  alleviating  previous  more
evere  restrictions  concerning  chronic  kidney  disease  and
iabetes  mellitus  patients.  Moreover,  for  elderly  patients,
oals  are  even  less  restrictive,  targeting  an  SBP  <  150  mmHg
epending  on  their  general  health  state.  The  decision  to
reat  takes  into  account  the  severity  of  hypertension  and
he  global  cardiovascular  risk.  Furthermore,  the  priority  is
iven  to  renin-angiotensin  system  blockers,  calcium  block-
rs  and  thiazides.  Renovascular  disease  largely  beneﬁts  from
he  prescription  of  renin-angiotensin  system  blockers.  No
ifference  is  made  between  conversion  enzyme  inhibitors
nd  angiotensin  blockers  and  their  combination  ﬁnds  no  indi-
ation.
onclusion
he  guidelines  from  France,  the  UK,  Europe  and  the  USA
n  the  management  of  hypertension  in  adults,  published
n  2013  and  2014,  arrived  at  different  recommendations  on
lood  pressure  goals  and  treatment  strategies.  The  respec-
ive  expert  panels  had  clearly  set  themselves  different
urop
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objectives.  The  stated  aim  of  the  French  panel  was  to  meet
the  need  for  a  short,  convenient  document  that  would  be
easy  to  use.  Taking  a  more  radical  approach,  particularly
regarding  treatment,  remained  the  driving  force  behind
the  UK  guideline.  In  the  USA,  the  big  issue  was  to  deﬁne
new  blood  pressure  goals,  with  the  added  bonus  of  reduc-
ing  health  expenditure  by  treating  fewer  patients.  The
European  guideline  is  exhaustive  and  addresses  every  situa-
tion,  incorporating  the  economic  differences  of  the  various
countries  within  and  beyond  Europe’s  borders.  These  differ-
ences  may  create  confusion  among  practitioners  as  well  as
patients.  They  also  affect  quality  indicators  for  target  goals
and  may  interfere  with  reimbursement  policy,  depending  on
the  health  system.  The  relevance  of  these  various  guide-
lines  could  be  assessed  by  studying  the  following  outcomes:
how  many  clinicians  read  them;  are  the  recommendations
applied;  and  how  effective  have  they  been  in  reducing  the
incidence  of  the  complications  of  hypertension  and  adverse
drug  effects?
Disclosure of interest
The  authors  declare  that  they  have  no  conﬂicts  of  interest
concerning  this  article.
References
[1] Blacher J, Halimi JM, Hanon O, et al. [Management of arte-
rial hypertension in adults: 2013 guidelines of the French
Society of Arterial Hypertension]. Ann Cardiol Angeiol (Paris)
2013;62:132—8.
[2] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC
Guidelines for the management of arterial hypertension: thee  and  the  USA  459
Task Force for the management of arterial hypertension
of the European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC). J Hypertens 2013;31:
1281—357.
3] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guide-
line for the management of high blood pressure in adults: report
from the panel members appointed to the Eighth Joint National
Committee (JNC 8). JAMA 2014;311:507—20.
4] Hypertension: the clinical management of primary hyperten-
sion in adults. Clinical Guideline 127: methods, evidence and
recommendations. London: National Clinical Guideline Centre;
2011. Available at: https://www.nice.org.uk/guidance/cg127/
evidence/cg127-hypertension-full-guideline3
5] HAS. Prise en charge des patients adultes atteints
d’hypertension artérielle essentielle. Actualisation; 2005. Avail-
able at: http://www.has-sante.fr/portail/jcms/c 240712/en/
prise-en-charge-des-patients-adultes-atteints-dhypertension-
arterielle-essentielle-actualisation-2005-dossier-de-presse
6] Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peter-
son ED. Proportion of US adults potentially affected by the 2014
hypertension guideline. JAMA 2014;311:1424—9.
7] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. The Heart Out-
comes Prevention Evaluation Study Investigators. N Engl J Med
2000;342:145—53.
8] Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular
morbidity and mortality in the Losartan Intervention For End-
point reduction in hypertension study (LIFE): a randomised trial
against atenolol. Lancet 2002;359:995—1003.
9] Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovas-
cular events with an antihypertensive regimen of amlodipine
adding perindopril as required versus atenolol adding ben-
droﬂumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA): a multicentre randomised controlled trial. Lancet
2005;366:895—906.
